DE10240818A1 - Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate - Google Patents

Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate Download PDF

Info

Publication number
DE10240818A1
DE10240818A1 DE10240818A DE10240818A DE10240818A1 DE 10240818 A1 DE10240818 A1 DE 10240818A1 DE 10240818 A DE10240818 A DE 10240818A DE 10240818 A DE10240818 A DE 10240818A DE 10240818 A1 DE10240818 A1 DE 10240818A1
Authority
DE
Germany
Prior art keywords
phenyl
pyrrolidin
oxadiazol
alkyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10240818A
Other languages
German (de)
English (en)
Inventor
Helmut Dr. Buschmann
Hagen-Heinrich Dr. Hennies
Bernd Dr. Sundermann
Corinna Dr. Sundermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grünenthal GmbH
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Priority to DE10240818A priority Critical patent/DE10240818A1/de
Priority to PCT/EP2003/009390 priority patent/WO2004024725A1/de
Priority to DE50313185T priority patent/DE50313185D1/de
Priority to MXPA05002298A priority patent/MXPA05002298A/es
Priority to ES03794933T priority patent/ES2351119T3/es
Priority to AT03794933T priority patent/ATE484503T1/de
Priority to CA002497078A priority patent/CA2497078A1/en
Priority to SI200331896T priority patent/SI1532141T1/sl
Priority to DK03794933.6T priority patent/DK1532141T3/da
Priority to AU2003264097A priority patent/AU2003264097B2/en
Priority to PT03794933T priority patent/PT1532141E/pt
Priority to PL03375627A priority patent/PL375627A1/xx
Priority to EP03794933A priority patent/EP1532141B1/de
Priority to JP2004535155A priority patent/JP2006506348A/ja
Priority to CNB038201976A priority patent/CN100390168C/zh
Priority to RU2005109164/04A priority patent/RU2324694C2/ru
Priority to PE2003000883A priority patent/PE20040983A1/es
Priority to ARP030103137A priority patent/AR041093A1/es
Publication of DE10240818A1 publication Critical patent/DE10240818A1/de
Priority to US11/066,981 priority patent/US7105538B2/en
Priority to CY20101101028T priority patent/CY1110913T1/el
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE10240818A 2002-08-20 2002-08-30 Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate Withdrawn DE10240818A1 (de)

Priority Applications (20)

Application Number Priority Date Filing Date Title
DE10240818A DE10240818A1 (de) 2002-08-30 2002-08-30 Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
AU2003264097A AU2003264097B2 (en) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
EP03794933A EP1532141B1 (de) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4] -oxadiazol-derivate und ihre verwendung als antidepressiva
MXPA05002298A MXPA05002298A (es) 2002-08-30 2003-08-25 Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazol y su uso como antidepresivos.
ES03794933T ES2351119T3 (es) 2002-08-30 2003-08-25 Derivados de 2-pirrolidin-2-il-[1,3,4 ]-oxadiazol y su utilización como antidepresivos.
AT03794933T ATE484503T1 (de) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
CA002497078A CA2497078A1 (en) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
SI200331896T SI1532141T1 (sl) 2002-08-30 2003-08-25 2-pirolidin-2-il-(1,3,4)-oksadiazolni derivati in njihova uporaba kot antidepresivi
DK03794933.6T DK1532141T3 (da) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
PCT/EP2003/009390 WO2004024725A1 (de) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivate und ihre verwendung als antidepressiva
PT03794933T PT1532141E (pt) 2002-08-30 2003-08-25 Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazole e sua utilização como antidepressivos
PL03375627A PL375627A1 (en) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
DE50313185T DE50313185D1 (de) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
JP2004535155A JP2006506348A (ja) 2002-08-30 2003-08-25 ２−ピロリジン−２−イル−［１，３，４］−オキサジアゾール−誘導体及びこれを抗うつ剤として使用する方法
CNB038201976A CN100390168C (zh) 2002-08-30 2003-08-25 2－吡咯烷－2－基－[1,3,4]－二唑衍生物和其作为抗抑制药的用途
RU2005109164/04A RU2324694C2 (ru) 2002-08-30 2003-08-25 Производные 2-пирролидин-2-ил-[1,3,4]оксадиазола и их применение в качестве антидепрессантов
PE2003000883A PE20040983A1 (es) 2002-08-30 2003-08-28 Derivados sustituidos del 2-pirrolidin-2-ilo[1,3,4]oxadiazol
ARP030103137A AR041093A1 (es) 2002-08-30 2003-08-29 Derivados sustituidos del 2-pirrolidin -2 -ilo [1,3,4] oxadiazol
US11/066,981 US7105538B2 (en) 2002-08-20 2005-02-28 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants
CY20101101028T CY1110913T1 (el) 2002-08-30 2010-11-17 Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10240818A DE10240818A1 (de) 2002-08-30 2002-08-30 Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate

Publications (1)

Publication Number Publication Date
DE10240818A1 true DE10240818A1 (de) 2004-05-13

Family

ID=31983895

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10240818A Withdrawn DE10240818A1 (de) 2002-08-20 2002-08-30 Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
DE50313185T Expired - Lifetime DE50313185D1 (de) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50313185T Expired - Lifetime DE50313185D1 (de) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva

Country Status (18)

Country Link
US (1) US7105538B2 (enExample)
EP (1) EP1532141B1 (enExample)
JP (1) JP2006506348A (enExample)
CN (1) CN100390168C (enExample)
AR (1) AR041093A1 (enExample)
AT (1) ATE484503T1 (enExample)
CA (1) CA2497078A1 (enExample)
CY (1) CY1110913T1 (enExample)
DE (2) DE10240818A1 (enExample)
DK (1) DK1532141T3 (enExample)
ES (1) ES2351119T3 (enExample)
MX (1) MXPA05002298A (enExample)
PE (1) PE20040983A1 (enExample)
PL (1) PL375627A1 (enExample)
PT (1) PT1532141E (enExample)
RU (1) RU2324694C2 (enExample)
SI (1) SI1532141T1 (enExample)
WO (1) WO2004024725A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
RU2417995C1 (ru) * 2009-09-21 2011-05-10 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") Способ получения 3-(2-замещенных-1,3-оксазол-4-ил)пиридин-2(1н)-онов
CN103420998A (zh) * 2012-05-16 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种新型噁二唑衍生物的合成方法
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
BR112015007516A2 (pt) * 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN105051040A (zh) * 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
CN103333165B (zh) * 2013-07-01 2016-02-24 河南理工大学 2-苯基-5-(3,4-二甲基)吡咯基-1,3,4-噁二唑及制备方法
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215949B1 (enExample) * 1973-02-01 1976-07-02 Delalande Sa
US4784998A (en) * 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
CN1382140A (zh) * 1999-07-09 2002-11-27 奥索-麦克尼尔药品公司 具有神经营养活性的吡咯烷和哌啶、以及含有它们的相关组合物
JP2001247569A (ja) * 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives

Also Published As

Publication number Publication date
MXPA05002298A (es) 2005-06-08
JP2006506348A (ja) 2006-02-23
PT1532141E (pt) 2010-11-02
EP1532141B1 (de) 2010-10-13
SI1532141T1 (sl) 2010-12-31
DK1532141T3 (da) 2010-11-22
CN1678609A (zh) 2005-10-05
ES2351119T3 (es) 2011-01-31
US20050187260A1 (en) 2005-08-25
CA2497078A1 (en) 2004-03-25
US7105538B2 (en) 2006-09-12
PE20040983A1 (es) 2005-01-12
AR041093A1 (es) 2005-05-04
AU2003264097A1 (en) 2004-04-30
EP1532141A1 (de) 2005-05-25
PL375627A1 (en) 2005-12-12
RU2324694C2 (ru) 2008-05-20
RU2005109164A (ru) 2006-01-20
DE50313185D1 (de) 2010-11-25
CY1110913T1 (el) 2015-06-10
CN100390168C (zh) 2008-05-28
ATE484503T1 (de) 2010-10-15
WO2004024725A1 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
DE69738382T2 (de) Heterozyklische Thioester und Ketone
CA2353460C (en) Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
DE19680256C2 (de) Verwendung kleiner Moleküle als Inhibitoren der Rotamase-Aktivität
EP1654253B1 (de) Substituierte 3-pyrrolidin-indol-derivate
DE69725345T2 (de) Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden
DE69435021T2 (de) Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit einem Diuretikum
JP2022539329A (ja) 特発性肺線維症を治療する方法
EP0998263A1 (en) Pyrrolidine derivative hair growth compositions and uses
JPH08505378A (ja) パーキンソン病およびパーキンソン病症候群の治療におけるリルゾールの用途
EP1532141B1 (de) 2-pyrrolidin-2-yl-[1,3,4] -oxadiazol-derivate und ihre verwendung als antidepressiva
DE69425085T2 (de) Angiotensin II Antagonisten als prophylaktisches und therapeutisches Mittel für Nierenkrankheiten
DE69402411T2 (de) Synergistishe kombination mit einer antagonistischen wirkung auf den nk1-und nk2- rezeptoren
AU1708199A (en) Aza-heterocyclic compounds used to treat neurological disorders and hair loss
DE69003924T2 (de) Verhinderung von Entzugserscheinungen.
DD298478A5 (de) Verwendung eines heteroaryl-3-oxo-propannitrilderivats und pharmazeutisches praeparat zur behandlung von auroimmunerkrankungen
DE60118914T2 (de) Pharmazeutische zusammensetzungen die acryloyl-substituierte distamycin-derivate und topoisomerase i und ii inhibitoren enthalten
DE69738320T2 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
EP0161501A1 (de) Antiulcermittel zur Behandlung von Geschwüren
US6943187B2 (en) Pyrrolidine derivative hair growth compositions and uses
EP1451177B1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol-derivative für die behandlung von migräne
DE69835543T2 (de) Haarwuchszusammensetzungen basierend auf einem heterozyklischen ester und keton und anwendungen
DE2502684C2 (enExample)
US20050059693A1 (en) Heterocyclic thioester and ketone hair growth compositions and uses
US6429215B1 (en) N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
KR20250050898A (ko) 기억력과 인지력 향상을 위한 조성물 및 방법

Legal Events

Date Code Title Description
OR8 Request for search as to paragraph 43 lit. 1 sentence 1 patent law
8105 Search report available
8110 Request for examination paragraph 44
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20120301